全文获取类型
收费全文 | 39163篇 |
免费 | 2645篇 |
国内免费 | 138篇 |
专业分类
耳鼻咽喉 | 415篇 |
儿科学 | 863篇 |
妇产科学 | 762篇 |
基础医学 | 4672篇 |
口腔科学 | 992篇 |
临床医学 | 4118篇 |
内科学 | 8198篇 |
皮肤病学 | 409篇 |
神经病学 | 3277篇 |
特种医学 | 1297篇 |
外国民族医学 | 1篇 |
外科学 | 6722篇 |
综合类 | 552篇 |
一般理论 | 26篇 |
预防医学 | 3205篇 |
眼科学 | 1220篇 |
药学 | 2546篇 |
中国医学 | 39篇 |
肿瘤学 | 2632篇 |
出版年
2023年 | 179篇 |
2022年 | 307篇 |
2021年 | 714篇 |
2020年 | 439篇 |
2019年 | 636篇 |
2018年 | 771篇 |
2017年 | 556篇 |
2016年 | 656篇 |
2015年 | 772篇 |
2014年 | 1125篇 |
2013年 | 1722篇 |
2012年 | 2468篇 |
2011年 | 2561篇 |
2010年 | 1454篇 |
2009年 | 1366篇 |
2008年 | 2348篇 |
2007年 | 2406篇 |
2006年 | 2418篇 |
2005年 | 2604篇 |
2004年 | 2507篇 |
2003年 | 2298篇 |
2002年 | 2181篇 |
2001年 | 300篇 |
2000年 | 238篇 |
1999年 | 378篇 |
1998年 | 517篇 |
1997年 | 417篇 |
1996年 | 353篇 |
1995年 | 346篇 |
1994年 | 283篇 |
1993年 | 266篇 |
1992年 | 229篇 |
1991年 | 204篇 |
1990年 | 170篇 |
1989年 | 158篇 |
1988年 | 156篇 |
1987年 | 173篇 |
1986年 | 152篇 |
1985年 | 187篇 |
1984年 | 269篇 |
1983年 | 267篇 |
1982年 | 380篇 |
1981年 | 335篇 |
1980年 | 310篇 |
1979年 | 159篇 |
1978年 | 202篇 |
1977年 | 207篇 |
1976年 | 197篇 |
1975年 | 153篇 |
1973年 | 151篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
The human visual system is amenable to a number of adaptive processes; one such process, or collection of processes, is the adaptation to blur. Blur adaptation can be observed as an improvement in vision under degraded conditions, and these changes occur relatively rapidly following exposure to blur. The potential important future directions of this research area and the clinical implications of blur adaptation are discussed. 相似文献
3.
4.
5.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
6.
7.
8.
Elissa A. Adame Ryan S. Bisel Edward S. Kosik Julia A. Rygaard 《Health communication》2019,34(6):638-643
An essential piece of anesthesiologist training is attending resident feedback sessions. Yet, few attending anesthesiologists have formal teaching education and little time to acquire it. In this field experiment, attending physicians were randomly assigned to a control group or to receive 30 minutes of feedback training inspired by Implicit Person Theory (IPT). As such, IPT training encouraged physicians to praise process-oriented learning while discouraging performance-oriented mindsets. Attending physicians then observed residents participate in a human patient simulation (HPS) activity and provided residents with feedback. Content and statistical analyses revealed trained attending physicians praised learning goals and challenged performance goals more often than untrained physicians during feedback sessions. Thus, the training provides a rapid method of enhancing the quality of attending physicians’ training communication. 相似文献
9.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献10.
Yinong Young-Xu Julia Thornton Snider Robertus van Aalst Salaheddin M. Mahmud Edward W. Thommes Jason K.H. Lee David P. Greenberg Ayman Chit 《Vaccine》2019,37(11):1484-1490